Human cellular toxicity was assessed in HepG2 cells using the CellTiter-Glo assay format, and data are shown above for the primary screening hit 1 (○) and 55 (•). Table S1 . Minimum bactericidal activity of ML267 (55). Cmpd. 55 n/a n/a n/a n/a Cmpd. 41 n/a n/a n/a n/a 
SUPPLEMENTAL METHODS

Label-free gel assay for phosphopantetheinylation
Test compound (0.5 µL) dissolved in DMSO was added to 1.33X enzyme solution (15 µL) containing 66 nM Sfp, 66 mM HEPES•Na pH 7.6, 13.3 mM MgCl 2 , 0.0133% NP40, and 1.33 mg/mL BSA. These solutions were incubated at room temperature for 10 minutes, at which point the phosphopantetheinylation reaction was initiated by the addition of 5X substrate solution (4 µL) containing 50 µM apo-ACP and 50 µM coenzyme A in 10 mM HEPES•Na pH 7.6. After incubation at room temperature for 30 minutes, quench/load solution (5 µL) containing 50 mM EDTA pH 8.0, 50% glycerol and 0.005% phenol red was added. The samples were electrophoretically separated on a discontinuous polyacrylamide gel using the Laemmli buffers sans SDS, with urea (2 M final) included in the resolving gel (15% total acrylamide/bisacrylamide concentration).
After separation, the gels were fixed (50% MeOH, 7% AcOH, 30 min), washed thrice with deionized water (200 mL, 5 min. per wash), and stained with Sypro Ruby® according to the manufacturer's recommendations. Imaging was accomplished with a Bio-Rad ChemiDoc TM XRS Gel Imager using standard ethidium bromide settings. Protein bands were quantified via densitometry using the ImageJ software package.
Mechanism of inhibition experiments: HPLC assay for phosphopantethienylation
Enzyme Reaction. Enzyme reactions were conducted in a 25 µL total assay volume in 384-well Greiner polypropylene plates. DMSO solution of test compound (0.5 µL) was added to a 1.25X solution of Sfp (20 µL, 37.5 nM) prepared in 1.25X HPLC assay buffer (62.5 mM MES-Na, 12.5 mM MgCl 2 , 0.0125% NP40, pH 6.0). After a 10 minute incubation at room temperature, reaction was initiated by the addition of 5.5X substrate solution (containing variable concentrations of CoA and ActACP in 10 mM HEPES-Na, pH 7.5). Following a 30 minute incubation, reactions were quenched by the addition of 50 mM EDTA, pH 8.0 (25 µL), and the plate was heat sealed. 1% v/v TFA) were prepared from HPLC grade solvents. The separation was accomplished as follows: after equilibration with 5% Buffer B, the samples were injected, and the mobile phase was ramped up to 50% Buffer B over 0.5 minutes, followed by an isocratic flow at this composition for 1.5 minutes. Separation of the apo-and holo-forms of ActACP was then achieved with a linear gradient from 50% to 70% Buffer B over 2 minutes. The mobile phase was then ramped to 95% Buffer B in 0.5 minutes, the column was washed by a 1 minute isocratic flow, and then adjusted to starting conditions with a 0.5 minute linear gradient to 5% Buffer B. Effective binding of the next sample required the inclusion of an end-run equilibration under this condition for 2 minutes. With this program, the two forms of the protein exhibited retention times of 4.7 and 5.3 minutes for the holo-and apo-forms of ActACP, respectively, with a typical baseline resolution between the peaks of 0.3 minutes. The absorbance trace recorded at 210 nm was baseline corrected, integrated, and the peak areas for holo-ActACP were normalized to positive and negative controls.
HPLC
Biochemical Reversibility Experiments
A DMSO solution of test compounds at a concentration 500 times their respective IC 50 (1 µL) were added to a 1.66 µM solution of Sfp (49 µL, dissolved in assay buffer (66 mM HEPES-Na, 13 mM MgCl2, 0.13% BSA, 0.013% NP40) and equilibrated at room temperature for 30 minutes. This solution was then serial diluted 10-fold twice in assay buffer containing 2% DMSO. The resulting solution (37.5 µL, 100-fold total dilution) was added to individual wells of a 384-well plate. Assay reactions were immediately initiated by the addition of a 4-X substrate solution (12.5 µL, containing 50 µM FiTC-YbbR peptide and 100 µM Rhodamine CoA dissolved in 10 mM HEPES-Na, pH 7.5), and the reaction time course was monitored in an Envision multilabel plate reader using the standard fluorescein settings.
Microbial susceptibility testing.
Innoculum preparation. Bacillus subtilis strains were maintained on lysogeny broth (LB) solidified by the addition of 1.5% w/v agar. Single colonies were used to inoculate cationadjusted mueller hinton II broth (2 mL) and shaken overnight at 30º C. In the morning, this culture (100 µL) was used to seed a fresh LB medium (10 mL) and was shaken at 30º C until the culture OD600 reached 0.5. This culture was diluted 1:100 in fresh cation-adjusted mueller hinton II broth to provide the inoculum below.
Bacterial susceptibility. Cation-adjusted mueller hinton II broth (2 µL) was dispensed into wells of a sterile white 1536-well plate. Test compounds (23 nL) prepared as serial dilutions in DMSO were added to the plate by pintool transfer. Innoculum (2 µL) was added; the plates were covered with a vented Kalypsys assay lid and incubated at 30 ºC. After 5 h, Bac-Titer Glo (4 µL; Promega Corp, Madison, WI) was added to the plates. They were incubated 10 minutes at room temperature, and then the luminescence was detected in a ViewLux multimodal plate reader.
HepG2 cytotoxicity counterscreen
Test compounds' toxicity was assessed by measuring cellular ATP content using a luciferasecoupled ATP quantitation assay (CellTiter-Glo; Promega, Madison, WI). In this assay, luminescent signal is proportional to amount of ATP, and thus to the number of metabolically competent cells. Briefly, HepG2 cells were dispensed at 2,000 cells/5 µL/well in tissue-culture treated 1,536-well white/solid bottom assay plates (Greiner Bio-One North America, Monroe, NC) using a Flying Reagent Dispenser (Aurora Discovery, Carlsbad, CA). Cells were incubated at 37 °C for 6 hr to allow for cell attachment, followed by addition of compounds via pin tool (Kalypsys, San Diego, CA). After compound addition, plates were incubated for 48 hr at 37 °C. At the end of the incubation period, 5 µL of CellTiter-Glo™ reagent was added, plates were incubated at room temperature in the dark for 30 min, and the luminescence intensity of each well was determined using a ViewLux plate reader (PerkinElmer, Shelton, CT). The positive S11 control was 92 µM and 41 µM of tetra-N-Octylammonium bromide, and the negative control was DMSO.
Membrane damage assessment assay
Assessments of membrane activity were performed in B. subtilis HM168 similarly to the protocol of Singh, 1 using the BacLight™ nucleic acid staining system (Invitrogen Corp, Carlsbad, CA, USA). The organism was maintained on LB medium solidified by the addition of bactoagar to 1.5% w/v, and all liquid culturing was performed in 250 mL baffled glass fernbach flasks containing 25 mL of LB medium. Bacterial cultures were grown from single colonies in LB medium at 30 ºC with shaking at 300 rpm. When the culture reached an OD of 0.5, the flask was chilled on wet ice for 10 min, and then the cells collected by centrifugation at 10,000 x g for 5 min. The cells were resuspended in sterile 0.85% NaCl (4 mL) and concentrated by centrifugation at 10,000 x g for 5 min. The cells were resuspended gently in 0.85% NaCl and adjusted to an OD value of 0.20. Cell suspension (50 µL) was added to 1.5 mL tubes containing a solution of test compounds dissolved in PBS (50 µL). The tubes were incubated at room temperature for 15 minutes, after which 11 µL of a 10 X BacLight™ solution (18 µL each of the Syto9 and propidium iodide solutions per mL deionized H 2 O) was added to the bacterial suspensions, and the cells were allowed to stain 5 minutes at room temperature. The bacterial suspensions were then used to prepare slides and were imaged on a Nikon Eclipse Ti inverted microscope with a 40 X objective using standard FITC and TRITC optical settings for Syto9 and propidium iodide, respectively.
Assay for surfactin biosynthetic capacity of B. subtilis
Innoculum preparation. Bacillus subtilis OKB105 was streaked for single colonies on trypticase soy agar from a frozen stock of vegetative cells and grown for 12 h at 30 ºC. A single colony was used to inoculate a seed culture of 10 mL cation-adjusted Mueller Hinton Broth-II (CA-MHB-II) in a 250 mL Fernbach flask, and the culture shaken in an Innova 42R incubator shaker possessing a 1 inch orbit (30 ºC at 300 RPM). When an OD 600 of ~1.0 was reached, the cells were collected by centrifugation (10 min at 4000 x g), resuspended in CA-MHB-II (10 mL) and again pelleted by centrifugation (4000 x g for 10 min). The cells were resuspended in 1.5 mL CA-MHB-II medium, adjusted to an OD 600 of 5, and used immediately as an innoculum for the cultures below.
Bacterial culture. 250 mL Fernbach flasks containing CA-MHB-II medium (25 mL) were prepared and the medium supplemented with Antifoam A (12.5 µL, 1% v/v solution; final concentration 0.0005% v/v) and test compound to the stated concentration by the addition of 100 X DMSO solution (250 µL, final DMSO concentration 1%). The flasks were innoculated with 250 µL of bacterial cells prepared as above to give a starting OD 600 = 0.05, and they were incubated with shaking (30 ºC, 300 RPM). Samples (1 mL) were collected every 2 hours, their OD 600 determined, and processed to determine the concentration of surfactin (vide infra).
Sample processing. 800 µL of bacterial culture was transferred to a 1.5 mL eppendorf tube and the cells pelleted by centrifugation at 17000 x g for 5 min. 700 µL of the resulting supernatant was flash frozen by transfer to 96w-deep well polypropylene plates (Bio-Rad, Hercules, CA) maintained on crushed dry ice throughout the experiment. After sample collection was complete, the plates were stored at -25 ºC.
Plates were subsequently thawed in a 37 ºC water bath and 300 µL of sample transferred into a new deep-well plate. Sample recovery standards (300 µL) were included in remaining rows of the plate. These plates were covered with aluminum seals, frozen on dry ice, the seals pierced with a 96 well-pin array ( The sample was then eluted with a 4 min linear gradient from these starting conditions to 90% B. This was followed by a 1 min linear gradient to 100% B, followed by a 0.2 min linear gradient back to 90% B. The solvent system was then stepped to 50% B to prepare the instrument for the next sample.
Data processing was conducted with Agilent Chemstations. The SIM trace centered on surfactin C (exact mass: 1035.68, [M+H]: 1036.68), the most abundant isomer, was analyzed for total ion count of the peak detected by the integrator between 1.5 and 3 minutes, and unknown sample concentrations were calculated from a standard curve prepared from a commercial sample of surfactin (S3523, Sigma Aldrich, St. Louis, MO).
Mouse model of S. aureus septicemia.
This experiment was conducted by the Anti-infectives Screening Core, NYU School of Medicine according to protocols approved by the NYU School of Medicine Institutional Animal Care and use Committee. Female Swiss Webster mice (30 animals, 5 weeks old) were infected intravenously with 1 x 10 7 CFU of S. aureus BK2395 (PFGE USA500) . The mice were divided into three cohorts of 10 animals each that received treatments at 4, 24, and 48 hours post infection with Compound 55 (30 mpk), vancomycin (50 mpk) or vehicle. Animals were monitored three times daily for 14 days, and the time of death recorded, which was indicated in this experiment as the point at which significant morbidity occurred (weight loss, ruffled fur, paralysis and inability to acquire food or water.
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Compound stability study protocol.
A 10 mM solution of 55 in DMSO (10 µL 
General Procedure A. Preparation of compounds 1-11, 19-21:
A mixture of the substituted amine (0.124 g, 1.0 mmol) and 1,1'-thiocarbonyldiimidazole (0.187 g, 1.05 mmol) in dichloromethane (2 mL) was stirred for 15 min at room temperature. 1-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazine (0.292 g, 1.1 mmol) was added to the clear yellow solution, and the reaction mixture was stirred at 40 o C for 1 h. The solvent was evaporated and the crude product was taken up in 2 mL DMSO and purified via reverse phase chromatography to afford compounds 1-11, 19-21 as TFA salts. -2-yl)-4-(3-(trifluoromethyl)phenyl) N-(4,6-dimethylpyridin-2-yl)-4-(3-(trifluoromethyl)phenyl) N-(quinolin-2-yl)-4-(3-(trifluoromethyl)phenyl) N-methyl-N-(4-methylpyridin-2-yl)-4-(3-(trifluoromethyl) 
N-(pyridin
1-(4-Methylpyridin-2-yl)-3-(3-(trifluoromethyl)phenyl)thiourea TFA (21). LC-MS Retention
Synthesis of N-(4-methylpyridin-2-yl)-4-(3-(trifluoromethyl)phenyl)piperazine-1carboximidamide TFA (13) (adopted from a literature method 3 ).
A mixture of N-(4methylpyridin-2-yl)-4-(3-(trifluoromethyl)phenyl)piperazine-1-carbothioamide (0.075 g, 0.197 mmol) and ammonium hydroxide (0.38 mL, 2.96 mmol, 15 eq) in DMF (1 mL) was added sodium periodate (0.046 g, 0.217 mmol, 1.1 eq) in water (0.5 mL). The reaction mixture was stirred at 80 °C for 1 h. After completion of the reaction, the crude product was purified via 
Synthesis of N'-cyano-N-(4,6-dimethylpyridin-2-yl)-4-(3-(trifluoromethyl)phenyl)piperazine-1-carboximidamide TFA (14) (adopted from a reported protocol 4 ).
A mixture of 4,6-dimethylpyridin-2-amine (0.2 g, 1.637 mmol, 1eq) and diphenyl cyanocarbonimidate (0.390 g, 1.637 mmol, 1 eq) in acetonitrile (5 mL N-(4,6-dimethylpyridin-2-yl)-5-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl) A mixture of 2-bromo-5-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)-1,3,4-thiadiazole (0.2 g, 0.509 mmol, 1eq), 4,6-dimethylpyridin-2-amine (0.093 g, 0.763 mmol, 1.5 eq), sodium tbutoxide (0.098 g, 1.02 mmol, 2 eq) and xantphos (0.029 g, 0.051 mmol, 10 mol %) in toluene (3 mL) was degassed with argon for 5 minutes. Pd 2 (dba) 3 (0.047 g, 0.051 mmol, 10 mol%) was then added and stirred at 110 o C for 3 h. The solvent was evaporated by blowing air and the crude product was dissolved in DMF then stirred with palladium scavenger for 30 min. The solution was filtered through a thiol cartridge and finally purified on a preparative HPLC to furnish pure N- (4,6- (17) (adopted from a reported method 6 ) . A mixture of 1-(4methylpyridin-2-yl)ethanone (0.2 g, 1.480 mmol, 1eq), 1-(3-(trifluoromethyl)phenyl)piperazine (0.417 mL, 2.220 mmol, 1.5 eq) and sulfur (0.059 g, 1.850 mmol, 1.25 eq) in DMF ( 4 mL) was heated under microwave irradiation at 130 °C for 30 minutes. The reaction mixture was filtered through a syringe filter and purified on a preparative HPLC to furnish 2-(4-methylpyridin-2-yl)-1-(4- 
Synthesis of 2-(((4,6-dimethylpyridin-2-yl)amino)(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)methyl-ene)malononitrile TFA (15) (adopted from a reported method 5 ). A mixture of 1-
Synthesis of
Synthesis of 2-(4-methylpyridin-2-yl)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1yl)ethanethione TFA
General procedures for the preparation of aryl piperazines. R 3 = 3-OCF 3 , 3-SO 2 Me, 3-OMe-5-CF 3 , 3-CF 3 -4-Cl,
General Procedure (modified from a reported method 7 ): A mixture of arylboronic acid (3.2 mmol, 2 eq), copper (II) acetate (0.029 g, 0.16 mmol, 10 mol %) and 4 Å molecular sieves (0.2 g) in dichloromethane (4 mL) was stirred for 5 minutes at room temperature. t-Butyl piperazine-1-carboxylate (0.3 g, 1.61 mmol, 1 eq) was then added, followed by bubbling with oxygen for 5 minutes. The vial was then sealed and filled with oxygen. The mixture was stirred overnight at 45 o C. After completion of the reaction, the reaction mixture was filtered through a metal scavenger cartridge (2 times to remove the copper completely). The crude products were then deprotected with TFA/dichloromethane as described in step D, and the products were either purified by HPLC or used directly in the next step.
General Procedure for Boc Deprotection (Step D):
Tert-butyl 4-arlylpiperazine-1-carboxylate (1 mmol, 1 eq) in dichloromethane (5 mL) was added trifluoroacetic acid (2 mL) and stirred at room temperature for 1 h. The reaction mixture was concentrated and dried under high vacuum.
The product was used as such in the next step.
R 3 = 3,5-CF 3 , 2-CF 3 -4-Cl,
General Procedure (procedure adopted from a reported method 8 ): A mixture of aryl bromide/aryl iodide (1 mmol, 1 eq), t-butyl piperazine-1-carboxylate (1.3 mmol, 1.3 eq), Cs 2 CO 3
S21
(1.5 mmol, 1.5 eq), BINAP (10 mol%) and Pd(OAc) 2 (5 mol%) in toluene (3 mL) was bubbled with argon for 5 minutes. The vial was capped and stirred at 110 o C for 12 -24 h. After completion of the reaction, the solvent was evaporated. The crude solid was dissolved in methanol/methylene chloride and stirred with a metal scavenger and filtered through celite. The crude products were purified on biotage® flash chromatography or reversed-phase HPLC and then deprotected with TFA as described in step D.
General Procedure (procedure adopted from a reported method 9 ): A mixture of aryl bromide (1 mmol, 1 eq), t-butyl piperazine-1-carboxylate (1.3 mmol, 1.3 eq), Na-O t Bu (1.5 mmol, 1.5 eq), JohnPhos (10 mol%) and Pd 2( dba) 3 (5 mol%) in toluene (3 mL) was bubbled with argon for 5 minutes. The vial was capped and stirred at 110 o C for 12 h. After completion of the reaction, the solvent was evaporated. The crude solid was dissolved in methanol/methylene chloride and stirred with a metal scavenger and filtered through celite. The crude product was purified on biotage® flash chromatography eluting with 25 % ethyl acetate in hexanes. The product was then deprotected with TFA using step D. General Procedure (procedure adopted from a reported method 10 ): A mixture of aryl iodide (1 mmol, 1 eq), tert-butyl piperazine-1-carboxylate (1.5 mmol, 1.5 eq), potassium phosphate (2 mmol, 2 eq), 1,1'-binaphthyl-2,2'-diol (0.2 mmol, 20 mol%) and copper(I)bromide (0.2 mmol, 20 mol%) in DMF (4 mL) was stirred at room temperature under nitrogen atmosphere for 12 h. The product was extracted with dichloromethane. The organic layer was successively washed with water, 1% HCl and brine, and dried with sodium sulfate. The crude product was purified on a biotage flash system eluting with 10 % ethyl acetate in hexanes. The product was deprotected with TFA as described in step D.
Synthesis of 5-(piperazin-1-yl)isophthalonitrile:
A mixture of 5-fluoroisophthalonitrile (0.5 g, 3.42 mmol, 1eq) and tert-butyl piperazine-1-carboxylate (1.275 g, 6.84 mmol, 2 eq) heated neat S22 at 120 o C for 1 h. The crude product was dissolved in CH 2 Cl 2 and treated with TFA as described in step D. The crude product obtained after evaporation of the solvent was purified in HPLC. N-(2,4-dimethylpyridin-2-yl)-4-(3-nitrophenyl) -(4,6-dimethylpyridin-2-yl)-4-(3,4,5-trichlorophenyl) N-(4,6-dimethylpyridin-2-yl)-4-(2,3,4-trichlorophenyl) N-(4,6-dimethylpyridin-2-yl)-4-(naphthalen-1-yl) -(4,6-dimethylpyridin-2-yl)-4-(3-(trifluoromethyl)benzyl) N-(4,6-dimethylpyridin-2-yl)-4-((3-(trifluoromethyl)phenyl) N-(4,6-dimethylpyridin-2-yl)-4-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl) N-(4,6-dimethylpyridin-2-yl)-4-(2-(trifluoromethyl)quinolin-4-yl) General procedure E (procedure adopted from a reported method 11 ): A mixture of 1-iodo-3-(trifluoromethyl)benzene (0.265 mL, 1.838 mmol, 1 eq), amine (2.76 mmol, 1.5 eq), copper(I) iodide (0.018 g, 0.092 mmol, 5 mol%) and cesium carbonate (1.20 g, 3.68 mmol, 2 eq) in DMF (7 mL) was degassed for 5 min and then 2-isobutyrylcyclohexanone (0.062 g, 0.368 mmol, 20 mol%) was added and stirred at 70 o C for 2-10 h. The product was extracted with ethyl acetate, successively washed with water, 1% HCl and brine. The organic layer was dried with sodium S30 sulfate and the crude product was purified on a biotage flash system eluting with 20% ethyl acetate in hexanes. The product was deprotected with TFA following the step D (above). 
N-(4-methylpyridin-2-yl)-4-(4-(trifluoromethyl)phenyl)piperazine-1-carbothioamide
N-(4,6-dimethylpyridin-2-yl)-4-(3-(trifluoromethoxy)phenyl)piperazine-1-carbothioamide
N-(4,6-dimethylpyridin-2-yl)-4-(3-(methylsulfonyl)phenyl)piperazine-1-carbothioamide
N-(4,6-dimethylpyridin-2-yl)-4-(3-methoxy-5-(trifluoromethyl)phenyl)piperazine-1-carbo-
N-(4,6-dimethylpyridin-2-yl)-4-(6-(trifluoromethyl)pyridin-2-yl)piperazine-1-carbothio-
Synthesis of compounds
N-(4-methylpyridin-2-yl)-3-(3-(trifluoromethyl)phenyl)imidazolidine-1-carbothioamide
